Fair Value Calculator Fair Value Calculator
EN DE

GPTHEALTH (GPTHEALTH) Fair Value & Analysis

Healthcare · Market cap ₹12.8B

G GPTHEALTH GPTHEALTH · NSE
Price₹156.47
Fair Value₹102.91
Upside-34.2%
Quality61/100
Watch GPTHEALTH for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹73.90 – ₹136.33

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price +3.3% over the past month.

Price vs Fair Value (12 months)

₹181.88 ₹115.31 Fair Value ₹102.91 Jul 2025 Jul 2026

12‑month range ₹115.31 – ₹181.88 · fair‑value band ₹73.90 – ₹136.33 · the ₹156.47 price screens above the ₹102.91 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

GPTHEALTH (GPTHEALTH) currently trades at ₹156.47, while our model-based Fair Value estimate is ₹102.91 — implying the stock looks roughly 34.2% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, GPTHEALTH generated revenue of ₹4.7B at a net margin of 8.9%. Revenue grew 24.6% year over year. It earns a return on equity of 16.3%. Net debt stands at ₹867M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹4.7B
Revenue growth (YoY) +24.6%
Net margin 8.9%
Return on equity 16.3%
Free cash flow ₹402M FY2025
P/E ratio 30.4
More key figures
Operating margin 13.0%
EPS (TTM) ₹5.15
Dividend yield 1.7%
EPS growth (YoY) +13.7%
Net debt ₹867M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

GPTHEALTH reported revenue of ₹4.7B in FY2025 versus ₹3.4B in FY2021, a compound +8.8%/yr. Reported net income was ₹422M in FY2025, compounding +0.3%/yr from FY2021.

Revenue +8.8%/yr
FY21 ₹3.4B
FY22 ₹3.6B
FY23 ₹4.0B
FY24 ₹4.2B
FY25 ₹4.7B
Net income +0.3%/yr
FY21 ₹417M
FY22 ₹390M
FY23 ₹478M
FY24 ₹499M
FY25 ₹422M

Is GPTHEALTH fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FSNUY $11.30 $8.61 -24%
5225 5225 8.71 MYR 4.87 MYR -44%
IHHHF IHHHF $1.71 $1.17 -32%
Tenet Healthcare Corporation THC $162.06 $282.55 +74%
Rede D'Or São Luiz S.A RDOR3 R$32.76 R$30.33 -7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is GPTHEALTH (GPTHEALTH) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹102.91 versus a price of ₹156.47 — about −34% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GPTHEALTH?
Our model-based fair value for GPTHEALTH is ₹102.91 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹156.47.
What is the quality score of GPTHEALTH?
GPTHEALTH has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of GPTHEALTH (GPTHEALTH)?
GPTHEALTH reported trailing-twelve-month revenue of about ₹4.7B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of GPTHEALTH?
The net profit margin of GPTHEALTH is about 8.9%, meaning it keeps roughly 8.9% of revenue as net income. Based on the latest reported figures.
Does GPTHEALTH pay a dividend?
GPTHEALTH currently shows a dividend yield of about 1.67% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.